CoVPN 5002, The COMPASS Study

CoVPN 5002 is designed to estimate the prevalence of SARS-CoV-2 in about 15 communities in the United States. The study enrolled approximately 26,000 people and results are expected in the spring of 2022. CoVPN 5002 will evaluate the impact of COVID-19 on these communities; assess knowledge, attitude and behavior about SARS-CoV-2 and COVID-19; model the potential impact of different prevention interventions; and inform rollout of future SARS-CoV-2 prevention studies and COVID-19 treatment studies in these communities. It will also provide valuable samples for important laboratory assessments related to the acquisition of SARS-CoV-2 and impact of the COVID-19 pandemic.

Visit www.COMPASSstudy.org or ClinicalTrials.gov - NCT04658121 for additional details.